Thomas Powles Selected Research

pazopanib

11/2020	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma.
11/2018	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
6/2017	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
10/2016	Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
4/2016	Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
3/2016	HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
1/2016	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
7/2015	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
3/2015	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
8/2014	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Powles Research Topics

Disease

147	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 03/2010
131	Neoplasms (Cancer) 04/2024 - 01/2004
75	Carcinoma (Carcinomatosis) 04/2024 - 06/2013
47	Kidney Neoplasms (Kidney Cancer) 01/2024 - 09/2008
40	Urinary Bladder Neoplasms (Bladder Cancer) 12/2023 - 01/2007
26	Disease Progression 03/2024 - 09/2011
19	Neoplasm Metastasis (Metastasis) 01/2023 - 12/2010
16	Prostatic Neoplasms (Prostate Cancer) 02/2023 - 12/2007
14	Fatigue 01/2023 - 11/2012
9	Hypertension (High Blood Pressure) 01/2022 - 07/2016
7	Urologic Neoplasms (Urological Cancer) 02/2024 - 01/2019
7	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2017 - 06/2010
4	Body Weight (Weight, Body) 03/2024 - 04/2018
4	Hypoxia (Hypoxemia) 10/2023 - 12/2012
4	Nausea 01/2023 - 08/2014
4	Diarrhea 01/2022 - 05/2014
4	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 10/2014
3	Pain (Aches) 02/2024 - 11/2014
3	Brain Neoplasms (Brain Tumor) 01/2024 - 11/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2018
3	Neutropenia 12/2020 - 01/2009
3	COVID-19 08/2020 - 01/2020
3	HIV Infections (HIV Infection) 02/2009 - 09/2008
2	Breast Neoplasms (Breast Cancer) 05/2023 - 12/2010
2	Exanthema (Rash) 01/2023 - 10/2016
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 01/2021
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Sepsis (Septicemia) 01/2021 - 11/2017
2	Colitis 01/2021 - 11/2017

Drug/Important Bio-Agent (IBA)

69	Sunitinib (Sutent)FDA Link 04/2024 - 09/2008
55	Immune Checkpoint InhibitorsIBA 04/2024 - 05/2017
47	atezolizumabIBA 04/2024 - 11/2014
42	PlatinumIBA 03/2024 - 01/2007
39	pembrolizumabIBA 04/2024 - 03/2017
34	Biomarkers (Surrogate Marker)IBA 03/2024 - 09/2011
34	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 01/2007
34	NivolumabIBA 11/2023 - 01/2016
32	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2024 - 06/2012
26	IpilimumabIBA 11/2023 - 03/2018
23	cabozantinibIBA 05/2023 - 11/2015
19	avelumabIBA 02/2024 - 03/2017
19	B7-H1 AntigenIBA 01/2022 - 11/2014
17	Everolimus FDA Link 12/2022 - 08/2014
16	Axitinib (AG 013736)IBA 03/2024 - 01/2018
14	LigandsIBA 11/2023 - 10/2015
12	Tyrosine Kinase InhibitorsIBA 10/2023 - 01/2013
12	pazopanib FDA Link 11/2020 - 11/2012
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2010
10	lenvatinibIBA 04/2024 - 03/2019
9	durvalumabIBA 10/2023 - 03/2017
9	Bevacizumab (Avastin)FDA Link 02/2022 - 01/2018
8	enfortumab vedotinIBA 03/2024 - 01/2021
8	Gemcitabine FDA Link 03/2024 - 06/2013
8	Docetaxel (Taxotere)FDA Link 01/2022 - 03/2015
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 11/2015
7	Carboplatin (JM8)FDA LinkGeneric 03/2024 - 01/2007
6	Alanine Transaminase (SGPT)IBA 01/2023 - 03/2016
5	Immunoconjugates (Immunoconjugate)IBA 09/2023 - 01/2023
5	DNA (Deoxyribonucleic Acid)IBA 07/2023 - 09/2015
5	Hormones (Hormone)IBA 05/2023 - 12/2014
5	Monoclonal AntibodiesIBA 01/2022 - 01/2018
5	RamucirumabIBA 01/2022 - 11/2017
4	Circulating Tumor DNAIBA 01/2024 - 01/2022
4	Lipase (Acid Lipase)FDA Link 01/2021 - 01/2018
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 06/2017
4	TOR Serine-Threonine KinasesIBA 01/2017 - 11/2014
3	cyclopropapyrroloindoleIBA 11/2023 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2020
3	EnzymesIBA 10/2022 - 01/2021
3	tremelimumabIBA 01/2021 - 12/2020
3	vinflunineIBA 01/2021 - 01/2018
3	AntibodiesIBA 10/2019 - 01/2018
3	Lapatinib (GW572016)FDA Link 11/2017 - 12/2010
3	ErbB Receptors (EGF Receptor)IBA 11/2017 - 03/2010
3	Irinotecan (Camptosar)FDA LinkGeneric 10/2014 - 09/2008
2	Phosphotransferases (Kinase)IBA 04/2024 - 10/2018
2	Hemoglobins (Hemoglobin)IBA 03/2024 - 01/2023
2	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 10/2023 - 09/2017
2	AntigensIBA 05/2023 - 01/2019
2	sacituzumab govitecanIBA 05/2023 - 01/2023
2	abirateroneIBA 02/2023 - 01/2022
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 01/2021
2	enzalutamideIBA 01/2022 - 03/2015
2	Complement System Proteins (Complement)IBA 10/2021 - 01/2021
2	Interleukin-8 (Interleukin 8)IBA 03/2021 - 01/2020
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 10/2016

Therapy/Procedure

143	Therapeutics 04/2024 - 12/2007
72	Drug Therapy (Chemotherapy) 03/2024 - 01/2004
38	Immunotherapy 03/2024 - 11/2014
31	Nephrectomy 10/2023 - 12/2010
13	Cystectomy 03/2023 - 04/2008
12	Neoadjuvant Therapy 01/2022 - 12/2007
9	Castration 01/2022 - 01/2010
7	Adjuvant Chemotherapy 02/2024 - 09/2012
4	Radiotherapy 02/2023 - 11/2014
4	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 05/2015
4	Aftercare (After-Treatment) 01/2021 - 01/2013
4	Highly Active Antiretroviral Therapy (HAART) 02/2009 - 03/2008
3	Nephroureterectomy 02/2024 - 01/2021
3	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 04/2008